Northwest Biotherapeutics Email Format

Biotechnology ResearchMaryland, United States11-50 Employees

Northwest Biotherapeutics, Inc. is a development-stage biotechnology company headquartered in Bethesda, Maryland, focused on immunotherapy approaches to cancer and employing a small team of 11 to 50 employees. The company develops DCVax, a platform that uses a patient's own dendritic cells loaded with tumor antigens to create personalized cancer vaccines that stimulate the immune system. Its lead product candidate, DCVax-Brain, targets glioblastoma multiforme and is in a Phase II FDA-allowed trial designed as a pivotal study, with plans to file a biologics license application with the FDA after the trial; a second candidate, DCVax-Prostate, is advancing in a Phase III pivotal trial. Northwest Biotherapeutics has expanded its operations as part of recent activity, including the opening of a leukapheresis clinic in London in 2026, the appointment of a strategic adviser, and the acquisition of Advent BioServices Ltd. in 2025. The company maintains its website at nwbio.com and operates within the biotechnology research industry.

Sign up for free to view info

Company overview Employee directory